HQY
HealthEquity Inc
NASDAQ: HQY · HEALTHCARE · HEALTH INFORMATION SERVICES
$81.65
+3.07% today
Updated 2026-06-05
Market cap
$7.36B
P/E ratio
32.96
P/S ratio
5.52x
EPS (TTM)
$2.67
Dividend yield
—
52W range
$73 – $117
Volume
1.0M
WallStSmart proprietary scores
66
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A7.8
Quality
B+7.5
Profitability
B+6.7
Valuation
B7/9
Piotroski F-Score
Strong
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$113.50
+39.01%
12-Month target
$74.48
-8.78%
Intrinsic (DCF)
$151.32
Margin of safety
+49.17%
5 Strong Buy10 Buy0 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Piotroski 7/9 — strong financial health
+ Free cash flow $97.16M — positive
+ 49.17% below intrinsic value
+ Debt/equity 0.48x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $861.75M | $999.59M | $1.20B | $1.31B | $1.34B |
| Net income | $-26.14M | $55.71M | $96.70M | $215.20M | $69.42M |
| EPS | — | — | — | — | $2.67 |
| Free cash flow | $31.52M | $196.75M | $337.77M | $455.13M | $97.16M |
| Profit margin | -3.03% | 5.57% | 8.06% | 16.38% | 17.20% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-29 | FIORE, MICHAEL HENRY | Sale | 3,142 | $95.00 |
| 2026-05-28 | WELLBORN, GAYLE FURGURSON | Sale | 2,439 | — |
| 2026-05-28 | WELLBORN, GAYLE FURGURSON | Buy | 2,439 | $47.21 |
Peer comparison
Smart narrative
HealthEquity Inc trades at $81.65. representing a P/E of 32.96x trailing earnings. Our Smart Value Score of 66/100 indicates the stock is good. The company scores 7/9 on the Piotroski F-Score. TTM revenue stands at $1.34B. with profit margins at 17.20%. Our DCF model estimates intrinsic value at $151.32.
Frequently asked questions
What is HealthEquity Inc's stock price?
HealthEquity Inc (HQY) trades at $81.65, on a P/E of 33.0x and a P/S of 5.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is HealthEquity Inc overvalued?
HealthEquity Inc carries a Smart Value Score of 66/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $151.32 versus the $81.65 price, a 49.2% margin of safety on a cash flow basis.
What is the price target of HealthEquity Inc (HQY)?
The 12-month analyst consensus target is $113.50, about 39.0% above the current $81.65. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of HealthEquity Inc (HQY)?
Our DCF model estimates intrinsic value at $151.32, a +49.2% margin of safety versus today's $81.65. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is HealthEquity Inc's revenue?
HealthEquity Inc's trailing twelve-month revenue is $1.34B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryHEALTH INFORMATION SERVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.52x
ROE10.21%
Beta0.19
50D MA$83.28
200D MA$88.42
Shares out0.08B
Float0.08B
Short ratio—
Avg volume1.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—